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Abstract Restrictocin is a toxin produced by the fungus 
Aspergillus restrictus. The DNA coding for restrictocin was 
isolated from the host by polymerase chain reaction and cloned 
into a T7 promoter-based expression vector. The protein was 
overproduced in Escherichia coli and remained insoluble in the 
cell in the form of inclusion bodies. Recombinant restrictocin was 
purified in large amounts, by a simple denaturation-renaturation 
protocol involving a redox system, with typical yields of 45 mg/l 
of original culture. Restrictocin could be secreted into the 
bacterial medium using ompA, pelB and LTB signal sequences. 
Among the three signal sequences, ompA was found to be the 
most efficient in secreting the recombinant protein. The protein 
secreted into the extracellular medium was properly processed as 
evident by the amino-terminal sequencing. Recombinant restric- 
tucin was readily purified to homogeneity from either the medium 
or inclusion bodies by simple chromatographic techniques and 
was found to be functionally as active as the native fungal protein 
in inhibiting the eukaryotic translation. 
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1. Introduction 
The ribonucleolytic toxin restrictocin belongs to a class of 
fungal ribotoxins that are extremely potent inhibitors of eu- 
karyotic protein synthesis [1]. Other members of the ribotoxin 
family include ct-sarcin and mitogillin [1,2]. Ribotoxins cleave 
a single phosphodiester bond on the 3' side of G4325 in a 
universal, 14-nucleotide, purine-rich sequence in the 28S 
rRNA,  thereby rendering eukaryotic ribosomes defective in 
elongation factor-1 (EF-1)-dependent binding of aminoacyl 
tRNA,  and in EF-2 catalyzed GTP hydrolysis and transloca- 
tion [3]. There are nearly 7000 nucleotides in mammalian ri- 
bosomes; the toxin, however, catalyzes only a single covalent 
modification that inactivates the ribosomes and is entirely 
responsible for the toxicity [4]. ~-Sarcin has been shown to 
possess anti-tumor activity [5]. The potent cytotoxic activity 
of the ribotoxins make them suitable molecules to be used in 
the construction of immunotoxins for targeted therapy of 
cancer and other diseases. Though restrictocin can be purified 
from the filtrate of A. restrictus, it is not desirable to handle 
the fungus in view of the fact that it is thought to be the 
causative agent of aspergillosis [6]. Earlier gene and cDNA 
coding for restrictocin have been expressed in Aspergillus ni- 
dulans and Saccharomyces cerevisiae, respectively, to study the 
role of leader peptide on the survival of the host [7,8]. Ribo- 
toxins, ~-sarcin and mitogillin have been expressed earlier 
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using ompA and pelB signal sequences but the protein levels 
obtained were low [9-13]. Asp f L a homologue of mitogillin 
has also been expressed in E. coli but the recombinant protein 
was 10-fold less active than the native toxin [14]. The aim of 
the present study was to produce authentic and functionally 
active ribotoxin restrictocin in large amounts in E. coli. The 
recombinant toxin could be employed in the construction of 
immunotoxins, and also could be used as a tool to study the 
eukaryotic translation machinery by investigating the interac- 
tion of ribotoxins with ribosomes. 
2. Materials and methods 
Enzymes and cell culture reagents were purchased from New Eng- 
land Biolabs and GIBCO-BRL, respectively. Low-melting-point agar- 
ose (Sea Plaque) was supplied by FMC Corp. [3H]Leucine was ob- 
tained from Amersham. Reagents for in vitro translation assay were 
from Promega and Pharrnacia. All other reagents were of analytical 
grade and obtained from Sigma. A. restrictus train 34475 was ob- 
tained from ATCC. 
2.1. Construction of plasmids 
DNA coding for restrictocin was amplified by polymerase chain 
reaction (PCR) using genomic DNA purified from the host, A. re- 
strictus as template. Published sequence of restrictocin gene was used 
for designing primers for PCR [7]. Various plasmids constructed for 
the current study are shown in Fig. 1. 
The PCR-amplified fragment of restrictocin was cloned as an NdeI 
EcoRI fragment in an E. coli expression vector pVexl 1 which contains 
phage T7 promoter and transcription terminator. The resulting plas- 
mid, pRest, contains restrictocin under the control of T7 promoter 
without any signal sequence. To generate secretion vectors, appropri- 
ate restriction sites were created by PCR on both ends of DNA coding 
for restrictocin and the amplified fragment after digestion cloned into 
vectors containing the required signal sequence as described below. To 
make pRestl, where restrictocin DNA is fused to that for the bacterial 
ompA signal sequence, restrictocin was cloned as an NdeI-EcoRI 
fragment in the vector pVexll5 which contains T7 promoter and 
ompA signal sequence. For making pRest2 containing restrictocin 
fused to the pelB signal sequence, DNA for restrictocin was cloned 
as an Nhel-EcoRI fragment into the vector pVNLSPA-AP0216 [15] 
which contains a T7 promoter and pelB signal sequence. To fuse 
restrictocin to the signal sequence, it was cloned as a SacI-HindlII 
fragment in the vector pMMB68 [16] containing tac promoter and 
LTB signal sequence giving rise to the plasmid pRest3. 
2.2. Expression and purification of restrictoc& 
E. coli strain BL21 (1DE3) was used for expression with all the 
vectors except pRest3, for which DH5ct cells were used. For the pur- 
ification of restrictocin from inclusion bodies, transformed cells were 
grown in super broth and induced at an 006oo of 2.0, with 1 mM 
IPTG for 2 h. Inclusion bodies were denatured in guanidine hydro- 
chloride and reduced by dithioerythritol (DTE), followed by renatura- 
tion in refolding buffer containing arginine and oxidized glutathione 
[17]. Renatured material, after dialysis, was loaded on a S-Sepharose 
column (Pharmacia), equilibrated with 20 mM MES, pH 5.0. In cases 
where the recombinant protein was secreted, medium or periplasm 
were loaded onto a S-Sepharose column directly after adjusting the 
pH to 5.0 using HCI. Restrictocin was eluted with a linear gradient of 
All rights reserved. 
260 D. Rathore et al./FEBS Letters 392 (1996) 259-262 
0 1 M NaCI in 20 mM MES, pH 5.0, using an FPLC system (Phar- 
macia). The S-Sepharose pool was further purified by gel filtration 
chromatography on a TSK 3000 column (LKB), if indicated. 
2.3. Spectroscopic characterization 
CD spectra were obtained on a JASCO J710 spectropolarimeter in 
the far-UV range at 25°C. The proteins were dissolved in 10 mM 
sodium phosphate buffer, pH 7.0. 
2.4. Assay of functional activity of recombinant restrictocin 
The activity of restrictocin was evaluated in a rabbit reticulocyte 
lysate based in vitro translation assay system. Rabbit reticulocyte 
lysate was prepared and the assay performed as described [18]. Ribo- 
nuclease activity of restrictocin was tested on yeast tRNA and syn- 
thetic Poly(A) and Poly(G) homopolynucleotides as described [19]. 
3. Results and discussion 
3.1. Construction of plasmids 
In order to produce restrictocin by recombinant means, we 
have cloned a cDNA encoding restrictocin in a T7 promoter- 
based E. coli expression vector (Fig. 1). The sequence of re- 
strictocin in pRest matched perfectly with the published se- 
quence. Restrictocin has also been cloned as fusion with 
ompA, pelB or LTB signal sequence respectively in pRestl,  
pRest2 and pRest3 (Fig. 1). 
3.2. Production and purification of restrictocin 
Restrictocin in bacterial cells transformed with pRest, 
which does not contain a signal sequence, was overexpressed 
as seen in the total cell pellet and remained in the spheroplast 
as insoluble inclusion bodies (Fig. 2A). Inclusion bodies were 
solubalized using guanidine hydrochloride and reduced by 
adding DTE. After renaturation, in the presence of oxidized 
glutathione, restrictocin could be purified to homogeneity by 
successive chromatography on cation exchange and gel filtra- 
tion columns (Fig. 2A). The protein after the cation exchange 
chromatography was nearly homogenous as from the subse- 
quent gel filtration column a single homogenous protein peak 
was obtained. For all further studies, therefore, protein was 
purified by a single-step purification on a cation exchange 
column. Although restrictocin can be obtained easily in large 
amounts from the inclusion bodies, we attempted to secrete 
restrictocin to compare the activity of recombinant protein 
refolded from the insoluble aggregates to that of the secreted 
protein. All three signal sequences used in the present study, 
directed the overexpressed protein to the medium, albeit, with 
different efficiencies. In addition, with pelB signal sequence 
pRest I 
pRest I ~ ] 
pRest 2 ~ "  ] 
pRest3 ~1~1 [ ] 
m T7 promoter [ ]  Tac promoter [ ]  Restdctocin 
[ ]  ompA Signal sequence: MKKTAIAIAVALAGFATVAQA~'AP 
• pelB Signal sequence: KYLLPTAAAGLLLLAAQPAMA~EA 
• LTB Signal sequence: MNKVKCYVLFTALLSSLYAHG ~'AP 
Fig. 1. Schematic representation f different constructs of restricto- 
cin. In pRestl, pRest2 and pRest3 restrictocin has been cloned be- 
hind ompA, pelB and LTB signal sequence, respectively, pRest does 
not contain any signal sequence. 
restrictocin was also present in the periplasmic space. The 
secretion of restrictocin into the medium with LTB signal 
sequence was much lower as compared to that using ompA 
and pelB signal sequences as shown on a quantitative western 
blot (Fig. 2B). Restrictocin was purified to homogeneity from 
the medium and periplasm on a single cation exchange col- 
umn. The comparative yields of purified protein from different 
sources are shown in Table 1. The yield was highest when 
restrictocin was purified from the inclusion bodies, i.e., 45 
mg/1. Among the various signal sequences used, ompA was 
found to be most efficient in secreting restrictocin and 4 mg of 
pure protein was obtained from a liter of culture. In the pres- 
ent investigation, the yields with ompA signal sequence are 
higher whereas those with pelB signal sequence are the same 
as reported by others [9,13]. 
3.3. Characterization of recombinant restrictocin 
3.3.1. Amino terminal sequencing 
Purified restrictocin from different sources was sequenced to 
check the authenticity of the protein. The amino-terminal se- 
quence of restrictocin from the inclusion bodies was found to 
be ATWTCINQQLNPKTNKWEDK which matched per- 
fectly with the published protein sequence [2]. The N-terminal 
sequences of soluble restrictocin purified from the culture 
medium of cells transformed with the plasmids with ompA, 
Table 1 
Yield and activity of recombinant restrictocin produced in E. coli 
Toxin Signal sequence Yield Activity 
(source) (mg/l) ID50 (pM) % Native 
Native Restrictocin - 7.0 35 100 
rRestrictocin (IB) None 45.0 35 100 
rRestrictocin (M) ompA 4.0 35 100 
rRestrictocin (M) pelB 0.4 35 100 
rRestrictocin (P) pelB 1.0 350 10 
rRestrictocin (M) LTB 0.3 35 100 
Ricin A chain - - 33 - 
Toxins were tested for their protein synthesis inhibitory activity in a cell-free translation assay, containing rabbit reticulocyte lysate. Rabbit 
reticulocyte lysate was prepared and the assay performed as described [18]. Serial dilutions of toxin were tested over a range of 0.05-500 ng/ml. 
Incorporation of [3H]leucine was measured as a function of toxin concentration. IDs0 is the concentration of toxin required to inhibit protein 
synthesis by 50% as compared to a control where no toxin was added. Activities of recombinant restrictocin from different sources were compared. 
M, medium; IB, inclusion bodies; P, periplasm. 
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Fig. 2. Purification of recombinant restrictocin. (A) pRest was used 
to transform BL210,DE3 ). A 12% SDS-polyacrylamide gelwas run 
and stained with Coomassie Blue. Lane 1, total cell pellet; lane 2, 
inclusion bodies; lane 3, protein after S-Sepharose column; lane 4, 
purified protein after gel filtration. (B) An immunoblot of a 12% 
SDS-polyacrylamide g l where equal volumes of culture superna- 
rants were loaded from different cultures grown to equal absorb- 
ence. Restrictocin was detected using polyclonal anti-restrictocin 
antibodies raised in rabbit. Molecular weight markers are shown 
x 10 -3 Da. 
pelB and LTB signal sequences were ahmATWTCIN, 
eAsWTCINQQ, and ApWTCINQQL, respectively. The N- 
terminal amino acid sequence of restrictocin purified from 
the periplasm of cells transformed with pRest2 was same as 
the N-terminus for protein purified from the medium of the 
same culture. The N-terminal sequence analysis confirmed 
that the processing of the mature protein was correct, and 
occurred at the engineered sites shown in Fig. 1. The changes 
from the native restrictocin N-terminus found in the first few 
amino acids of secreted restrictocin are shown in lower case, 
and were expected because of the inclusion of enzyme recog- 
nition sites for cloning purposes. 
3.3.2. Spectroscopic characterization of  purified proteins 
The far-UV CD spectra of purified restrictocin from the 
fungal host culture medium, secreted using the ompA signal 
sequence, and isolated from the bacterial inclusion bodies 
have been compared in Fig. 3. The secondary structure values 
obtained from CD measurements are shown in Table 2. The 
values for recombinant protein isolated from inclusion bodies 
and native restrictocin are in good agreement with those re- 
ported for ct-sarcin, a known homologue of restrictocin [20], 
and the values obtained for restrictocin from Garnier method 
of secondary structure prediction [21]. The CD spectral char- 
acteristics of the native protein and that isolated from the 
inclusion bodies were similar indicating that the recombinant 
restrictocin purified from the inclusion bodies was conforma- 
Table 2 
Secondary structure analysis of restrictocin 
Native Inclusion Secretory Predicted a 
bodies 
Helical 21.1 18.9 13.9 18.7 
sheet 20.5 13.9 32.9 12.0 
Turn 25.0 24.9 15.4 28.1 
Random coil 33.3 41.8 39.3 40.9 
The secondary structure analyses from the CD measurements were 
performed by using Yang reference parameters [25] 
~Secondary structure prediction by the method of Garnier [21]. 
tionally close to the native protein produced by the fungal 
host. 
3.3.3. In vitro ribonucleolytic activity of recombinant 
restrictocin 
The recombinant restrictocin was tested in a cell-free system 
using rabbit reticulocyte lysate, for its inhibitory activity to- 
wards protein synthesis. Recombinant restrictocin purified 
from inclusion bodies was found to be as potent as the native 
toxin secreted by the host and inhibited translation of globin 
mRNA with an IDs0 of 35 pM (Table 1). Although protein 
from soluble sources had a modified N-terminus containing 
either a few extra amino acids or changes, enzymatic activity 
was same as that of the native protein, indicating that a few 
additions or changes at the amino terminus are well tolerated 
and do not affect the enzymatic activity of the protein. The 
protein purified from the insoluble inclusion bodies contains 
similar activity to that of the native or secreted recombinant 
restrictocin, implying that using a protocol involving a redox 
system protein refolded correctly and attained its native con- 
formation. Activity of the recombinant protein was similar to 
ricin A chain, another ribosomal inactivating protein that acts 
on the same intracellular target. Recombinant restrictocin 
purified from periplasm was found to be 10-fold less active 
than restrictocin purified from the medium or inclusion bodies 
(Table 1). This loss of activity could be due to improper 
folding as has been shown for some other recombinant pro- 
teins secreted into the periplasm [22,23]. Recombinant restric- 
tocin also showed ribonuclease activity when synthetic homo- 
polynucleotides were used as substrates. As shown in Fig. 4, 
the toxin caused extensive digestion of Poly(A) and moderate 
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Fig. 3. CD spectra of restrictocin purified from different sources. 
Far-UV spectra of restrictocin purified from fungal culture medium 
( - . - ) ,  bacterial culture medium (---), and bacterial inclusion 
bodies ( ). Mean residue llipticity is expressed asdegree cm -1 
dmol 1. 
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Fig. 4. Ribonuclease activity of recombinant restrictocin. Activity 
was measured on yeast RNA (O), and synthetic polyribonucleotides 
Poly(A) (i) and Poly(G) (O). Yeast tRNA (40 gg) or homopoly- 
mers (40 nmol) were incubated for 60 min, at 40°C in 50 mM 
Tris.HC1, pH 7.3, with different concentrations of the toxin. Undi- 
gested RNA was precipitated on cold with perchloric acid and ura- 
nyl acetate. Precipitated material was removed by centrifugation 
and the absorbence of the supernatant was read at 260 nm. 
hydrolysis of Poly(G). Restrictocin caused degradation of 
yeast tRNA in a dose-dependent manner (Fig. 4). Since re- 
strictocin unlike RNaseA is a specific ribonuclease, a more 
pronounced inhibitory activity in a cell-free protein synthesis 
assay confirms specific recognition of the target ribosomal 
RNA by the recombinant proteins. In addition, its preferen- 
tial activity on Poly(A) is in agreement with the earlier report 
on a-sarcin [24]. 
Earlier Asp f L a homologue of restrictocin, has been re- 
natured and purified from insoluble source; however, the re- 
combinant protein was found to be 10-fold less active than the 
native toxin [14]. This reduction in enzymatic activity has been 
attributed to misfolding of the recombinant toxin due to the 
presence of a histidine fusion peptide at the amino terminus of 
the recombinant toxin used in the purification of the recom- 
binant Asp f I [14]. In the present study, the recombinant 
restrictocin purified from the insoluble inclusion bodies has 
an authentic amino terminus and contains full enzymatic ac- 
tivity. 
In conclusion, we have shown that the ribotoxin restrictocin 
could be over-produced in E. coli and purified to homogeneity 
by a single-step urification protocol. Using the protocol em- 
ployed, large amounts of functional recombinant protein 
could be obtained from the inclusion bodies. Properly pro- 
cessed and functional restrictocin is secreted with the help of 
ompA, pelB and LTB signal sequences, ompA being the most 
efficient in secretion. Small modifications at the amino termi- 
nus of restrictocin do not affect its enzymatic activity. 
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